Enrollment and Randomization of 12463 Participants Complete in BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine trial - P&T Community

Enrollment and Randomization of 12463 Participants Complete in BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine trial  P&T Community

Comments

Popular posts from this blog